CellaVision Future Growth
Future criteria checks 5/6
CellaVision is forecast to grow earnings and revenue by 22.8% and 12.9% per annum respectively. EPS is expected to grow by 22.7% per annum. Return on equity is forecast to be 22.8% in 3 years.
Key information
22.8%
Earnings growth rate
22.7%
EPS growth rate
Medical Equipment earnings growth | 36.6% |
Revenue growth rate | 12.9% |
Future return on equity | 22.8% |
Analyst coverage | Low |
Last updated | 02 Dec 2024 |
Recent future growth updates
CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 24Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10Recent updates
Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 24Is CellaVision (STO:CEVI) A Risky Investment?
Jun 07Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?
May 22CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25
Apr 13CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price
Apr 09CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Mar 28CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
Mar 14CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 29After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Feb 16CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 12Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
Dec 13Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Sep 14Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 22CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return
Jun 17CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's
May 07Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)
Apr 19CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25
Apr 05CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year
Mar 04CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be
Feb 11Is CellaVision (STO:CEVI) A Risky Investment?
Jan 13Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?
Dec 13CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly
Sep 23CellaVision (STO:CEVI) May Have Issues Allocating Its Capital
Aug 16Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 02We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease
Jun 27What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?
May 31Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 970 | 238 | 202 | 281 | 4 |
12/31/2025 | 849 | 196 | 147 | 222 | 4 |
12/31/2024 | 742 | 146 | 143 | 226 | 4 |
9/30/2024 | 737 | 150 | 152 | 229 | N/A |
6/30/2024 | 726 | 145 | 183 | 261 | N/A |
3/31/2024 | 708 | 141 | 168 | 249 | N/A |
12/31/2023 | 677 | 130 | 110 | 196 | N/A |
9/30/2023 | 629 | 112 | 60 | 148 | N/A |
6/30/2023 | 602 | 97 | 23 | 106 | N/A |
3/31/2023 | 616 | 99 | 38 | 118 | N/A |
12/31/2022 | 639 | 118 | 68 | 137 | N/A |
9/30/2022 | 651 | 126 | 93 | 155 | N/A |
6/30/2022 | 642 | 142 | 114 | 173 | N/A |
3/31/2022 | 594 | 135 | 87 | 171 | N/A |
12/31/2021 | 566 | 125 | 75 | 160 | N/A |
9/30/2021 | 532 | 114 | 62 | 139 | N/A |
6/30/2021 | 488 | 101 | 13 | 87 | N/A |
3/31/2021 | 471 | 98 | 44 | 82 | N/A |
12/31/2020 | 471 | 89 | 37 | 71 | N/A |
9/30/2020 | 490 | 85 | 40 | 71 | N/A |
6/30/2020 | 498 | 89 | 80 | 107 | N/A |
3/31/2020 | 492 | 92 | 68 | 90 | N/A |
12/31/2019 | 462 | 99 | 107 | 126 | N/A |
9/30/2019 | 423 | 104 | 94 | 114 | N/A |
6/30/2019 | 412 | 104 | 87 | 107 | N/A |
3/31/2019 | 391 | 97 | 98 | 119 | N/A |
12/31/2018 | 365 | 89 | 51 | 74 | N/A |
9/30/2018 | 330 | 76 | 67 | 91 | N/A |
6/30/2018 | 307 | 67 | N/A | 77 | N/A |
3/31/2018 | 294 | 63 | N/A | 69 | N/A |
12/31/2017 | 309 | 70 | N/A | 88 | N/A |
9/30/2017 | 306 | 70 | N/A | 93 | N/A |
6/30/2017 | 313 | 78 | N/A | 89 | N/A |
3/31/2017 | 300 | 75 | N/A | 86 | N/A |
12/31/2016 | 265 | 60 | N/A | 76 | N/A |
9/30/2016 | 254 | 57 | N/A | 54 | N/A |
6/30/2016 | 260 | 66 | N/A | 80 | N/A |
3/31/2016 | 246 | 55 | N/A | 59 | N/A |
12/31/2015 | 239 | 53 | N/A | 88 | N/A |
9/30/2015 | 250 | 49 | N/A | 70 | N/A |
6/30/2015 | 223 | 30 | N/A | 49 | N/A |
3/31/2015 | 226 | 34 | N/A | 53 | N/A |
12/31/2014 | 217 | 31 | N/A | 40 | N/A |
9/30/2014 | 209 | 33 | N/A | 59 | N/A |
6/30/2014 | 207 | 36 | N/A | 47 | N/A |
3/31/2014 | 189 | 26 | N/A | 49 | N/A |
12/31/2013 | 180 | 19 | N/A | 27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CEVI's forecast earnings growth (22.8% per year) is above the savings rate (1.2%).
Earnings vs Market: CEVI's earnings (22.8% per year) are forecast to grow faster than the Swedish market (14.7% per year).
High Growth Earnings: CEVI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CEVI's revenue (12.9% per year) is forecast to grow faster than the Swedish market (1.3% per year).
High Growth Revenue: CEVI's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CEVI's Return on Equity is forecast to be high in 3 years time (22.8%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 19:05 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Sten Gustafsson | ABG Sundal Collier |
Bjorn Rydell | ABG Sundal Collier Sponsored |
Carl-Oscar Bredengen | Berenberg |